Accordingly, the combination of LCMV and tumour-specific CD8+ T cells was most effective in suppressing tumour growth in the B16F10 melanoma model and in the EL4 subcutaneous lymphoma model (Fig. 4d,e). Here, CD8A is linked to lymphoma.